Salmonella

Chicken salmonella enteritidis infection related biomarker and application thereof

Resumen de: CN119876424A

The invention discloses a chicken salmonella enteritidis infection related biomarker and application thereof, and belongs to the technical field of poultry genetic breeding and propagation. The invention finds that the content of RUNX2 transcription factors in cecum T cells infected by salmonella enteritidis is obviously different, the expression quantity of RUNX2 in a susceptible group is far higher than that of RUNX2 in a resistance group, which indicates that the RUNX2 is a susceptible gene infected by salmonella enteritidis, and if a chicken shows typical enteritis symptoms such as diarrhea, inappetence and the like and the expression level of RUNX2 is detected to be obviously increased, the RUNX2 is a susceptible gene infected by salmonella enteritidis. This may be a marker of a chicken susceptible to Salmonella enteritidis; if the chicken does not show corresponding symptoms and the expression level of the RUNX2 is not greatly increased, the chicken is indicated to have resistance to the salmonella enteritidis, the resistance of the chicken to the infected salmonella enteritidis can be identified on the molecular level through a single-cell transcriptomics technology, and a technical support is provided for breeding poultry varieties resistant to salmonella enteritidis infection.

Lactobacillus clavuliformis HAU121, microbial inoculum and application of lactobacillus clavuliformis HAU121

Resumen de: CN119875946A

The invention belongs to the technical field of agricultural biology, and particularly relates to a strain of lactobacillus coryniformis HAU121, a microbial inoculum and application of the microbial inoculum. The microbial inoculum comprises lactobacillus coryniformis HAU121, lactobacillus coryniformis HAU121, lactobacillus coryniformis HAU121, lactobacillus coryniformis HAU121 and lactobacillus coryniformis HAU121. According to the invention, a strain of lactobacillus clavuliformis HAU121 is screened from rumen fluid of dairy cow, the strain has stable acid production performance, and the stable acid production performance ensures that the strain rapidly inhibits the growth of other microorganisms in the fermentation process; bacteriostatic activity detection finds that the strain HAU121 has different degrees of inhibition capability on escherichia coli, staphylococcus aureus, salmonella and pseudomonas aeruginosa. The strain HAU121 provided by the invention is applied to solid anaerobic fermentation of cottonseed meal, the removal rate of free gossypol in the fermented cottonseed meal can reach 75.20%, and the strain HAU121 has no obvious negative influence on the nutritional value of the cottonseed meal, and has important application value in the aspect of feed development and utilization of the cottonseed meal.

Antibacterial mouthwash and preparation method thereof

Resumen de: CN119868246A

The invention belongs to the field of oral care products and provides antibacterial mouthwash which is prepared from the following raw materials in percentage by mass: 20-30% of lactobacillus plantarum powder, 25-30% of plant extract, 10-15% of humectant, 2-3% of preservative and 0.5-2% of pH regulator. 5-12% of an antibacterial synergist; 2-3% of a sweetening agent and 17-35% of deionized water; the plant extracts comprise a honeysuckle flower extract, a Philippine violet herb extract, a left-hand fragrant extract, a tea leaf extract and a licorice root extract; lactobacillus plantarum powder is provided by Shanghai Shanghai Shanghai Shanghai Detection Technology Co., Ltd., and the product number is BNCC299253. The toothpaste can play a good role in protecting helicobacter pylori, salmonella, listeria monocytogenes, enterobacter sakakaakii and the like, can relieve swelling and aching of gum, oral mucosa bleeding and other symptoms, and avoids halitosis. And the toothpaste also has a very good prevention effect on diseases such as oral ulcer, gingivitis and periodontitis.

Primer group for detecting mcr-1 to mcr-10 and application

Resumen de: CN119876431A

The invention discloses a primer group for detecting polymyxin drug resistance genes (mcr-1 to mcr-10) of bacteria, a multiplex PCR (Polymerase Chain Reaction) method and application. The primer group comprises 10 pairs of primers which are respectively used for carrying out specific PCR (Polymerase Chain Reaction) amplification on mcr-1 to mcr-10 genes. Based on the primer group, a one-step multiplex PCR method for efficiently detecting the genes from mcr-1 to mcr-10 is established. According to the method disclosed by the invention, efficient, specific and sensitive detection of mcr-1 to mcr-10 genes can be realized through one-step reaction of a reaction system. The method provided by the invention is used for detecting escherichia coli and salmonella isolates and comparing with a genome sequencing result, so that the accuracy of the method provided by the invention is further verified. The invention fills the blank of lack of mcr-1 to mcr-10 gene multiplex PCR primer groups and methods at present, and has good application prospects in the fields of clinical detection and microbial prevention and control.

Salmonella phage JN06 and application thereof

Resumen de: CN119876046A

The invention discloses a salmonella bacteriophage JN06 and an application thereof. The preservation number of the salmonella phage JN06 is GDMCC (China General Microbiological Culture Collection Center) No: 65479-B1, and the salmonella phage JN06 is preserved in Guangdong Province Microbial Culture Collection Center on November 13, 2024. The Salmonella lyase has the advantages that the Salmonella lyase is simple in preparation method and wide in host spectrum, not only can be used for lysing various serotypes of salmonella, particularly can be used for lysing Salmonella Schwarzenge Salmonella vaporariorum, but also can be used for lysing Escherichia coli at the same time. The method has the advantages of short incubation period, high outbreak amount, strong tolerance to temperature and pH value, wider application range, and no virulence gene and drug-resistant gene.

Novel method for detecting salmonella, application and detection kit

Resumen de: CN119881118A

The invention belongs to the technical field of food-borne pathogenic bacterium detection, and discloses a detection method for targeted analysis and detection of salmonella based on a characteristic peptide, and the method detects salmonella pollution in a dairy product by analyzing the following characteristic peptides: I1: (LLADDLVPSR; i2: (IGTISTTGEMSPLDAR), and I3: ( I3: (IELALFLDSYIPEPER), and a method for preparing the same. And I4: (AVAAVEELK). The method for identifying the type of the strain by taking the characteristic peptide as an index is a relatively safe food detection method, the characteristic peptide of a specific microorganism is used for screening, and the characteristic peptide is detected through a targeted mass spectrometry analysis technology, so that the detection of pathogenic bacteria is converted into the detection of the characteristic peptide. The method has the advantages of rapidness, high throughput, high reliability, no dependence on bacterial colony purity and the like. By obtaining a characteristic peptide combination with good specificity, the technology can realize detection of various specific microorganisms.

Biomarker for detecting salmonella enteritidis infection and application of biomarker in preparation of salmonella enteritidis infection detection kit

Resumen de: CN119876374A

The invention relates to the technical field of molecular biology, in particular to a biomarker for detecting salmonella enteritidis infection and application of the biomarker in preparation of a salmonella enteritidis infection detection kit. The invention provides a biomarker for detecting salmonella enteritidis infection, and the biomarker is long-chain RNA (Ribonucleic Acid) Lnc012227. The invention provides a novel molecular marker which can be used for diagnosing and monitoring the infection condition of salmonella in duck ovaries, the characteristic can be used as a reference for evaluating the resistance potential of offspring, a novel strategy and a tool are provided for prevention and control of salmonella infection in the laying duck industry, and the application prospect is wide. The reproductive performance of the laying ducks and the safety of the duck eggs are favorably improved.

Antibiotic carrier based on bacterial outer membrane vesicles and preparation method thereof

Resumen de: CN119875903A

The invention provides a preparation method of an antibiotic carrier based on bacterial outer membrane vesicles, which is characterized by comprising the following steps: (1) culturing bacteria in a culture medium containing antibiotics; and (2) removing viable bacteria in the culture product, and extracting the outer membrane vesicles of the bacteria to obtain the antibiotic carrier based on the outer membrane vesicles of the bacteria, wherein the bacterium is a salmonella mutant strain QS0074, and the preservation number of the bacterium is CCTCC (China Center For Type Culture Collection) M 2023192; the antibiotic is alcamicin. The antibiotic carrier based on the bacterial outer membrane vesicles, provided by the invention, has excellent drug loading capacity on the acamicin, and has relatively good drug activity stability; the preparation method is simple and easy to popularize.

VBNC salmonella enteritidis resuscitation medium and application

Resumen de: CN119875961A

The invention relates to a VBNC salmonella enteritidis resuscitation culture medium and application, and belongs to the technical field of microorganism culture detection. The VBNC salmonella enteritidis resuscitation culture medium comprises 8 g/L-12 g/L of peptone, 3 g/L-7 g/L of sodium chloride, 7 g/L-11 g/L of disodium hydrogen phosphate, 1 g/L-2 g/L of monopotassium phosphate and 0 U/mL-1000 U/mL of Rpf recombinant protein. Experiments prove that the culture medium can detect VBNC salmonella enteritidis which cannot be detected by a traditional culture medium, and the VBNC salmonella enteritidis resuscitation culture medium is proved to be excellent in performance and high in detection rate.

TUMOR NEOANTIGEN VACCINE SYSTEM SPECIFICALLY MARKING HETEROLOGOUS PROTEIN, AND USE THEREOF

Resumen de: WO2025081515A1

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

METHOD FOR PREPARING BIOFLOC CULTURE MEDIUM BY USING ORGANIC WASTES

Resumen de: WO2025081938A1

Provided is a method for preparing a biofloc culture medium by using organic wastes. The method comprises: adding a first auxiliary material to organic wastes, uniformly mixing same to obtain a mixture, and adjusting the water content of the mixture to 45-55%; inoculating an activated Bacillus subtilis seed culture, Bacillus licheniformis seed culture and Saccharomyces cerevisiae seed culture into the mixture according to a ratio, and performing fermentation with stirring and ventilation, so as to obtain a fermented product; adding a second auxiliary material to the fermented product, and uniformly mixing same to obtain the biofloc culture medium. In the finished biofloc product prepared by the method, the viable count of Bacillus subtilis is greater than or equal to 400 million cfu/g, the viable count of Bacillus licheniformis is greater than or equal to 200 million cfu/g, the viable count of Saccharomyces cerevisiae is greater than or equal to 1200 million cfu/g, the total number of bacterial colonies is greater than or equal to 8000 million cfu/g, and no salmonella is detected. The present application can solve the pollution problem of livestock and poultry manure and further achieves recycling utilization of livestock and poultry manure.

IMMUNOSTIMULATORY COMPOSITION

Resumen de: US2025127889A1

The present disclosure relates to a composition for inducing migration of activated B cells to a germinal center, the composition including a substance that induces CD11b expression in B cells, a production method therefor, or use thereof. In one aspect, the present disclosure relates to immunostimulation and maintenance or improvement of mucosal flora using the substance that induces the CD11b expression in B cells.

標的微生物を検出するための反応媒体、及び関連する方法

Resumen de: AU2023262222A1

The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.

Methods of using symbiotic compositions to resist salmonella typhimurium infection

Resumen de: CN119855897A

The present invention provides a method for producing a recombinant bacterium, which is characterized in that the recombinant bacterium is used for producing a recombinant bacterium, and the recombinant bacterium is obtained by using a recombinant bacterium, which is preserved in the Deersche Sammlarg von Mikroorgani sung Zel lkulturen and has been preserved in the Deersche Sammlarg von Mikroorgani sung Zel lkulturen with a preservation number of DSM 32786. The present invention relates to a method for resisting Salmonella typhimurium infection by using a culture of Lactobacillus rhamnosus LRH10 having a preservation number of DSMZ GmbH, Lactobacillus paracasei LPC12 having a preservation number of DSMZ GmbH, Lactobacillus fermentum LF26 having a preservation number of DSMZ GmbH, Streptococcus thermophilus ST30 having a preservation number of DSMZ 32788, and Lactobacillus helveticus LH43 having a preservation number of DSMZ 32787, and more specifically, to a method for resisting Salmonella typhimurium infection by using a culture of Lactobacillus rhamnosus LRH10 having a preservation number of DSMZ GmbH.

Lactobacillus rhamnosus and application thereof

Resumen de: CN119842544A

The invention belongs to the field of microorganisms, and relates to lactobacillus rhamnosus and application thereof. The lactobacillus rhamnosus KC3 is separated from Xinjiang healthy bactrian camel milk, and the lactobacillus rhamnosus KC3 has the activity of inhibiting various pathogenic bacteria such as escherichia coli, klebsiella pneumoniae, salmonella, proteus mirabilis, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and streptococcus agalactiae. The metabiotics of the strain can enhance the sensitivity of pathogenic bacteria such as escherichia coli and staphylococcus aureus to antibiotics such as beta-lactam antibiotics, and can synergistically enhance the antibacterial effect of the beta-lactam antibiotics to the pathogenic bacteria such as escherichia coli, staphylococcus aureus, CRE or MRSA. The lactobacillus rhamnosus KC3 metagen can also destroy cell walls of pathogenic bacteria such as escherichia coli, staphylococcus epidermidis, CRE or MRSA and the like, and the formation of bacterial biofilms is inhibited.

鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用

Resumen de: CN119842745A

本发明公开了鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用。本发明选择强毒力鼠伤寒沙门菌SL1344株作为亲本株，将其中降解代谢衣康酸的关键毒力基因Ict进行敲除，构建鼠伤寒沙门菌SL1344减毒疫苗候选株。通过小鼠动物毒力实验、免疫保护力实验和安全性实验等证实该疫苗候选株SL1344‑ΔIct缺失株，不仅对动物的致病力显著降低，且提供了良好的免疫原性和免疫保护力。本发明实现对强毒力鼠伤寒沙门氏菌株的减毒，可广泛应用于沙门菌的防控，为研制沙门菌的减毒活疫苗及活载体疫苗奠定基础。

VACCINE COMPOSITIONS COMPRISING SIALIC ACID BINDING DOMAIN (SBD) PROTEINS AND USE THEREOF TO ENHANCE IMMUNE RESPONSE

Resumen de: WO2025080776A2

Aspects of the invention described herein relate to a vaccine composition comprising at an antigenic polysaccharide and an immunomodulatory amount of a sialic acid binding moiety, wherein the sialic acid binding moiety comprises sialic acid binding domain (SBD) which is not fused to an antigenic polypeptide.

Duplex fluorescent PCR detection primer probe group for duck salmonella enteritidis and salmonella typhimurium, kit, and use thereof

Resumen de: GB2634693A

A duplex fluorescent PCR detection primer probe group of duck Salmonella enteritidis and Salmonella typhimurium, a kit, and the use thereof. Comparative analysis on the whole genomes of Salmonella enteritidis and Salmonella typhimurium is performed to screen out as identification targets a specific fragment Sdf I of lyg D gene of Salmonella enteritidis and a specific gene STM4497 of Salmonella typhimurium, and the present application designs specific primers and probes.

Quadruple digital PCR (Polymerase Chain Reaction) detection kit for simultaneously detecting four intestinal bacterial pathogens in sewage and application of quadruple digital PCR detection kit

Resumen de: CN119824115A

The invention discloses a quadruple digital PCR (Polymerase Chain Reaction) detection kit for simultaneously detecting four intestinal bacterial pathogens in sewage and application of the quadruple digital PCR detection kit. The invention relates to a quadruple digital PCR (Polymerase Chain Reaction) detection kit, which comprises primers and probes, wherein the primers and the probes are respectively used for detecting salmonella spp., shigella spp., vibrio cholerae and vibrio parahaemolyticus, and the primers and the probes are respectively used for detecting salmonella spp., shigella spp., vibrio cholerae and vibrio parahaemolyticus. Furthermore, the invention also provides an application of the quadruple digital PCR detection kit in preparation of a reagent for simultaneously detecting salmonella, shigella, vibrio parahaemolyticus and vibrio cholerae. When the kit is used for detecting four intestinal bacterial pathogens in sewage, the detection flux is greatly improved, a technical means is provided for efficient development of large-scale sewage monitoring projects, and potential disease outbreak risks can be accurately recognized in the early stage.

Transaminase mutant and application thereof in asymmetric synthesis of L-glufosinate-ammonium

Resumen de: CN119823960A

The invention discloses a transaminase mutant and application of the transaminase mutant in asymmetric synthesis of L-glufosinate-ammonium. The transaminase mutant is obtained by carrying out single-point saturated mutation or iterative saturated mutation on 13th, 17th, 19th or 22th amino acids of an amino acid sequence shown as SEQ ID NO.1. The invention further discloses a preparation method of the transaminase mutant. The invention provides a novel high-activity transaminase mutant derived from salmonella, and the whole-cell relative enzyme activity of different mutants reaches 250.1%-397.9% compared with that before mutation.

Application of fangchinoline in prevention and treatment of salmonella infection

Resumen de: CN119818497A

The invention discloses an application of fangchinoline in prevention and treatment of salmonella infection. The fangchinoline alkali is an isoquinoline alkaloid, and is a host-oriented treatment natural compound. The fangchinoline disclosed by the invention has a relatively strong effect of treating salmonella infection diseases in vivo and in vitro, and specifically, the fangchinoline can effectively reduce the quantity of intracellular infection bacteria. Administration of the fangchinoline can significantly reduce the load of pathogenic bacteria in the liver, spleen, colon, cecum and ileum of a mouse, and reduce the proinflammatory factor level of an organism. In-vivo and in-vitro safety shows that the fangchinoline has no toxic or side effect below the test dosage. Besides, the fangchinoline alkali and the fluoroquinolone medicine are combined for use, so that the remarkable synergistic antibacterial activity is achieved, and the remarkable synergistic antibacterial activity is shown in reducing the number of salmonella infection bacteria in cells and reducing the load of pathogenic bacteria in the liver, the spleen and the colon of a mouse. The invention provides a new perspective for the development of novel anti-infection drugs, and also provides a new idea for the prevention and control of increasingly serious salmonella infection.

Hippophae rhamnoides seed meal antibacterial peptide as well as preparation method and application thereof

Resumen de: CN119823220A

The invention relates to the technical field of antibacterial peptide preparation, and particularly discloses a hippophae rhamnoides seed meal antibacterial peptide and a preparation method and application thereof.The hippophae rhamnoides seed meal antibacterial peptide is prepared through the steps that hippophae rhamnoides seed meal is smashed, sieved, degreased, dissolved and centrifuged to obtain hippophae rhamnoides seed meal crude protein, then protease is used for enzymolysis, and the hippophae rhamnoides seed meal crude protein is obtained; centrifuging, taking supernatant, and freeze-drying to obtain the sea-buckthorn seed meal antibacterial peptide; the protease is selected from any one of trypsin, alpha-chymotrypsin and alkaline protease. The hippophae rhamnoides seed meal antibacterial peptide prepared by the invention can inhibit staphylococcus aureus, escherichia coli and salmonella.

Rapid diagnosing Composition for detecting multiple Salmonella enterica serovars

Resumen de: KR20250049691A

본 발명은 살모넬라 혈청형 동시 검출을 위한 신속 진단 조성물에 관한 것으로서, 본 발명에서는 인간에서 발병률이 높은 여러 살모넬라 엔테리카(Salmonella enterica) 혈청형을 진단하기 위한 신속 도트-블롯 면역분석법을 개발하였다. 10개의 상업용 항체(4개의 다클론 항체 및 6개의 단클론 항체)에 대한 적용 가능성을 2016년 미국에서 67.5%의 살모넬라 감염 사례와 관련된 18개의 혈청형을 사용하여 시험하였다. Ab 3(다클론; 18개 혈청형 중 8개), Ab 8(단클론; 18개 혈청형 중 13개) 및 Ab 9(단클론; 18개 혈청형 중 10개) 항체는 웨스턴 블롯에서 높은 검출율을 나타냈고, 두 항체의 조합(Ab 3+8, Ab 3+9 및 Ab 8+9)을 도트-블롯 분석에 적용하였다. Ab 3+8의 조합은 시험된 18개의 혈청형 중 15개를 식별할 수 있었는데, 이는 S. Enteritidis, S. Typhimurium, S. Javiana, S. I 4,5,12:i:-, S. Infantis, S. Montevideo, S. Braenderup, S. Thompson, S. Saintpaul, S. Heidelberg, S. Oranienburg, S. Bareilly, S. Berta, S. Agona 및 S. Anatum을 포함하며, 2016년 미국에서 53.7%의 살모넬라 감염 사례와 관련되어 있다. 본 발명에서 최적화한 면역분석법은 3시간 안에 주요 15종의 혈청형을 진단할 수 있고, 이러한 비용 효율적이고 신속한 방법은 살모넬라 검출을 위한 현장 비색 방법으로 유용하게 활용될 수 있을 것으�

Phytobacterium plantarum with bacteriostatic effect and application thereof

Resumen de: CN119799598A

The invention discloses a plant lactobacillus with a bacteriostatic effect and application of the plant lactobacillus. The lactobacillus plantarum is named as lactobacillus plantarum C07, the preservation number is CCTCC NO: M20242086, the preservation unit is China Center for Type Culture Collection, the preservation time is September 26, 2024, and the preservation address is Wuhan University, Wuhan University, No. 299, eight road, Wuchang District, Wuhan City, Hubei Province. The strain can produce lactic acid and indole-3-lactic acid at high yield, has a very strong antibacterial effect on multiple putrefying and pathogenic microorganisms such as staphylococcus aureus, escherichia coli, listeria monocytogenes, pseudomonas aeruginosa, salmonella and mould, and is a broad-spectrum antibacterial microorganism.

Eubacterium mucilaginosus E11405 and application thereof in bacteriostasis and anti-inflammation

Nº publicación: CN119799564A 11/04/2025

Solicitante:

NAT INSTITUTE FOR COMMUNICABLE DISEASE CONTROL AND PREVENTION CHINESE CENTER FOR DISEASE CONTROL AND
\u4E2D\u56FD\u75BE\u75C5\u9884\u9632\u63A7\u5236\u4E2D\u5FC3\u4F20\u67D3\u75C5\u9884\u9632\u63A7\u5236\u6240

Resumen de: CN119799564A

The invention relates to the technical field of microorganisms, in particular to Eubacterium mucilaginosus E11405 and application thereof in bacteriostasis and anti-inflammation. The preservation number of the mucus eubacterium is CGMCC (China General Microbiological Culture Collection Center) No.31231. The application comprises inhibition of microorganisms and anti-inflammation. The microorganisms comprise one or more of listeria monocytogenes, staphylococcus aureus, salmonella typhimurium or escherichia coli. The Eubacterium mucilaginosus provided by the invention can relieve various infection symptoms caused by salmonella infection, and shows the potential in preparation of drugs for treating and/or preventing infection of pathogenic bacteria such as salmonella. In addition, the Eubacterium mucilaginosus provided by the invention can also effectively relieve inflammatory bowel diseases and relieve intestinal mucosa injury and colitis symptoms, provides a new strategy for preventing and treating inflammatory bowel diseases, and has potential clinical application prospects.